Is Mounjaro an SGLT2 Inhibitor? Understanding Its Drug Class

You searched this because you've seen both names in the same conversation

Picture the scene: you're reading about medicines for type 2 diabetes or weight loss, and a cardiologist's letter or a forum post mentions SGLT2 inhibitors in the same breath as GLP-1 medicines. Suddenly you're wondering whether Mounjaro falls into that bucket too. It does not, and the distinction is worth understanding clearly rather than just taking someone's word for it.

SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) block a protein in the kidney tubules that recycles glucose back into the bloodstream. When that protein is inhibited, excess glucose spills into the urine, lowering blood-sugar levels. Medicines in this class include dapagliflozin (Forxiga), empagliflozin (Jardiance) and canagliflozin (Invokana). They are taken as daily tablets and are licensed primarily for type 2 diabetes, with additional licensed indications covering heart failure and chronic kidney disease.

Mounjaro works upstream of all of that. Its active ingredient, tirzepatide, binds to two receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Activating both prompts the pancreas to release insulin in response to meals, suppresses glucagon, slows the rate at which the stomach empties, and significantly reduces appetite. The result is lower blood sugar and, in people living with obesity, meaningful weight loss. You can read more about tirzepatide's pharmacology and clinical background if you want the fuller picture. The NHS medicines page for tirzepatide also sets out how it works in plain language.

The two classes are sometimes combined in diabetes management (a prescriber might use both together because they target different systems) but that is a clinical decision, not something to self-navigate.

What Mounjaro is licensed to treat in the UK, and what SGLT2 inhibitors are not

Mounjaro holds a UK licence for two indications: weight management in adults with a BMI of 30 or above (or 27 or above with at least one weight-related health condition), and type 2 diabetes. Its weight-management licence is what makes it relevant to people visiting a service like Mounjaro through a regulated UK pharmacy. SGLT2 inhibitors do not hold a weight-management licence in the UK; they are not prescribed for weight loss as a primary goal, even though modest weight reduction is a recognised secondary effect.

This distinction matters practically. If you have been told about SGLT2 inhibitors by your GP for diabetes or heart failure management, that conversation sits in a different clinical lane from weight-management treatment. They may coexist in a treatment plan, but they are answering different clinical questions.

NICE's appraisal of tirzepatide (TA1026) sets out the specific NHS eligibility criteria for Mounjaro (BMI thresholds, required comorbidities, phased rollout cohorts) and private eligibility under the licensed SmPC runs alongside it with somewhat broader criteria. If you are curious about what those thresholds mean for you personally, our page on talking to a prescriber about Mounjaro covers the kinds of questions a clinical review involves.

One practical check you can do right now: look up any medicine name on the NHS medicines pages and you will see its licensed indications listed clearly at the top. It takes under a minute and quickly settles whether a medicine belongs to the class you think it does.

Side-effect profiles: not the same picture

Because the mechanisms differ so fundamentally, the side-effect landscapes of Mounjaro and SGLT2 inhibitors are quite different. Knowing which applies to Mounjaro is useful if you are weighing up whether to pursue a consultation.

Mounjaro's most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and reduced appetite. These tend to cluster around the start of treatment and after dose increases, often settling within days to a couple of weeks as the body adjusts. More serious but infrequent risks include pancreatitis, the MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients to seek urgent help for severe, persistent abdominal pain that radiates to the back, with or without vomiting. Injection-site reactions, fatigue and headache are also reported. You can read a thorough breakdown of the risk profile on our page covering what Mounjaro's safety record actually shows.

SGLT2 inhibitors, by contrast, carry a different set of considerations: urinary tract and genital infections (because glucose in the urine creates a hospitable environment for bacteria and yeast), a small risk of diabetic ketoacidosis, and in rare cases a serious skin infection called Fournier's gangrene. These risks are absent from Mounjaro's profile because the kidney mechanism that causes them is simply not involved.

If you are on an SGLT2 inhibitor and considering adding or switching to a GLP-1/dual-agonist medicine, that is a conversation for your GP or specialist, both classes can affect kidney function and fluid balance in ways that require monitoring. Our page on what monitoring looks like during Mounjaro treatment explains the checks a prescriber typically considers.

The short version, if you want it

Mounjaro is not now, and has never been, an SGLT2 inhibitor. It is a dual GIP and GLP-1 receptor agonist, a class that acts through gut hormones rather than the kidneys. The two groups of medicines can complement each other clinically, but they are not interchangeable and do not belong in the same pharmacological category.

If you arrived here because you are trying to understand your own options for weight management or metabolic health, the next useful step is a proper clinical conversation. On the weight-loss treatment overview you will find a comparison of the medicines a prescriber at a regulated UK pharmacy can consider for you. Thinking about cost as part of that decision is reasonable too, our guide to what Mounjaro costs privately in the UK sets out what a transparent price should include and what questions to ask any provider.

When you are ready to have your circumstances reviewed by a real clinician rather than a search engine, you can check your eligibility with our prescribers. A GPhC-registered prescriber reads every consultation personally, the same day it arrives.